Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

This study is testing a combined treatment approach for mycosis fungoides — a type of skin lymphoma — using low-dose full-body radiation (electron beam therapy) given alongside a targeted drug called brentuximab vedotin, delivered quarterly over 12 months. **You may be eligible if...** - You have biopsy-confirmed mycosis fungoides at any stage (I–IV) - Your cancer has returned or stopped responding to previous treatments - Your tumor cells express at least 1% of a protein called CD30 - You have received prior treatments for this cancer **You may NOT be eligible if...** - Your Sezary cell count in the blood is 1,000 or more per microliter at the time of enrollment - You have had prior brentuximab vedotin treatment with unacceptable toxicity - You have significant nerve damage (peripheral neuropathy) of grade 2 or higher - You have active serious infections or other major health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.